| Combination of | |
|---|---|
| ethambutol | anti-tuberculosis medication |
| isoniazid | anti-tuberculosis medication |
| rifampicin | anti-tuberculosis medication |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Ethambutol/isoniazid/rifampicin, also known as ethambutol/isoniazid/rifampin, is a fixed-dose combination medication used to treat tuberculosis. It contains ethambutol, isoniazid, and rifampicin. It is used either along or with other anti-tuberculosis medication. It is taken by mouth. Side effects are those of the underlying medications. Use may not be suitable in children.
It is on the World Health Organization's List of Essential Medicines.
See also
References
- ^ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 142. hdl:10665/44053. ISBN 9789241547659.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Further reading
- World Health Organization (February 2008). Rifampicin, Isoniazid, and Ethambutol hydrochloride (PDF) (Report). World Health Organization. QAS/07.220/FINAL.
External links
- "Ethambutol". Drug Information Portal. U.S. National Library of Medicine.
- "Isoniazid". Drug Information Portal. U.S. National Library of Medicine.
- "Rifampin". Drug Information Portal. U.S. National Library of Medicine.
| Antimycobacterials, including tuberculosis treatment and leprostatic agents (J04) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nucleic acid inhibitor |
| ||||||||
| Protein synthesis inhibitor |
| ||||||||
| Cell envelope antibiotic |
| ||||||||
| Other/unknown | |||||||||
| Combinations | |||||||||
| |||||||||
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |